Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…Influence of controlled-release levodopa on quality of sleep and nocturnal movements
Objective: To evaluate the effects of controlled-released (CR) levodopa on quality of sleep and nocturnal movements as assessed with mobile health technology in patients with…A framework to facilitate competence in practice for Parkinson’s Disease Nurse Specialists in the United Kingdom
Objective: To determine if the current Parkinson's Disease Nurse Specialist (PDNS) competency framework 2nd Edition 2008 (1) for nurses working in the management of Parkinson's…Neurological improvement with WTX101 treatment in a Phase 2, multi-center, open label study in Wilson Disease
Objective: The objective of this study was to characterize neurological manifestations in Wilson Disease (WD) patients and describe specific neurological changes after 24 weeks’ treatment…Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics
Objective: To evaluate the real-world long-term effectiveness of CLES on advanced PD patients and their caregivers. Background: Carbidopa/levodopa enteral suspension (CLES) was approved in USA…Improving compliance to Parkinsonism’s pharmacotherapy amongst patients attending a Movement Disorders Clinic (MDC)
Objective: To improve patients’ compliance with Parkinsonism's pharmacotherapy to achieve more accurate clinical assessment in an outpatient setting. Background: Patients with Parkinsonism are encouraged to…SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results
Objective: To evaluate the safety and preliminary efficacy of SYN120 in patients with Parkinson's disease dementia (PDD). Background: SYN120 is an antagonist of serotonin receptors…Exploring The Role of a Prescribing Pharmacist in the Management of Parkinson’s Disease
Objective: Aims/Objectives A review to explore the role of a pharmacist NMP within the neurology PD multidisciplinary team during a six month period between 1st…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 32
- Next Page »